Lab marker
Lipoprotein(a)
Lp(a) · Lipoprotein little-a
A heritable, near-unmodifiable atherogenic particle. Most people should know their level once; the result almost never changes.
What it measures
Lipoprotein(a) is an LDL-like particle covalently bound to apolipoprotein(a). Concentration is ~70–90% genetically determined and stable for life from young adulthood. Elevated Lp(a) is an independent causal risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis.
Reference context
4 guideline sources
Roughly 20% of the global population carries elevated Lp(a) (>125 nmol/L), often clinically silent until an early CV event. No current therapy specifically lowers Lp(a) outside of trials (pelacarsen Phase III ongoing); knowing your level shapes how aggressively you target other modifiable risk factors (ApoB, BP, smoking).
Population context: consult guideline targets below
Mechanism
Why moving this marker matters
Lp(a) particles enter the arterial wall like LDL but resist clearance and additionally promote thrombosis and inflammation. Mendelian-randomisation studies have established causality for ASCVD and aortic stenosis.
Guideline targets
What major guidelines recommend
EAS 2022 consensus (risk unlikely to be raised)
<75 nmol/L (<30 mg/dL)
EAS 2022 consensus (risk-enhancing)
>125 nmol/L (>50 mg/dL); values in between are a grey zone
ESC/EAS 2019 (very high)
>430 nmol/L (>180 mg/dL): lifetime risk similar to heterozygous familial hypercholesterolaemia
ACC/AHA 2018
≥50 mg/dL is a risk-enhancing factor justifying earlier or more intensive lifestyle/pharmacotherapy decisions
How to measure
The test, where to get it, when to repeat
Method
Standard blood draw. Modern assays report in nmol/L (mass-independent, preferred) or mg/dL. Fasting not required.
Where
Through your GP on request, or private lab. Often not on standard panels; must usually be requested specifically.
Typical cost
€15–40 private.
Fasting
Not required
When to test
ESC 2019 dyslipidaemia
20+Measure at least once in every adult's lifetime; reasonable in young adulthood. Repeat testing usually not needed.
EAS 2022 consensus
Measure Lp(a) at least once in every adult's lifetime to identify very high inherited levels.
Where to test
Independent labs offering this test
Healicus refers you to independent laboratories. You order from the lab; they take the sample, run it, and return your result on their own platform. Healicus never sees your value.
Randox Health
UK · EU · INTLClinic-based premium panels — wider biomarker breadth than home-test brands.
Visit Randox Health
Synlab
DE · EU · INTLEurope-wide medical lab network — referrals via partner GPs and direct-to-consumer programmes where offered.
Visit Synlab
Medichecks
UKUKAS-accredited home blood-test panels with GP-equivalent biomarker coverage.
Visit Medichecks
Thriva
UKApp-first subscription home testing, capillary draw, clinician-reviewed reports.
Visit Thriva
Healicus is not the provider. Your contract for the service is with whoever you choose. Links labelled Sponsored are paid affiliate relationships; unlabelled links are editorial reference only. See our disclosure for the full policy.
Context
Reading the numbers
Roughly 20% of the global population carries elevated Lp(a) (>125 nmol/L), often clinically silent until an early CV event. No current therapy specifically lowers Lp(a) outside of trials (pelacarsen Phase III ongoing); knowing your level shapes how aggressively you target other modifiable risk factors (ApoB, BP, smoking).
Caveats
Assay variability between methods is meaningful; track in the same units (nmol/L preferred). Acute inflammation can transiently elevate Lp(a).
See also
Related markers
Take to your physician
Worth discussing
- Whether your Lp(a) shifts your overall cardiovascular risk estimate enough to change action.
- How aggressively to target other modifiable risk factors (ApoB, BP, smoking) given a non-modifiable elevated Lp(a).
- Family history: first-degree relatives have a meaningfully elevated probability of also being high.
Sources
Cited literature
- [1]ESC/EAS 2019 Guidelines for the management of dyslipidaemias(2019)
- [2]Kronenberg et al., Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement (Eur Heart J)(2022)
- [3]Grundy et al., 2018 ACC/AHA Cholesterol Guideline, risk-enhancing factors(2018)
Last reviewed October 2026
Keep reading